A Case of Rapidly Progressing Hepatocellular Carcinoma after Administration of JAK Inhibitors to Treat Rheumatoid Arthritis

We report a case of rapidly progressing hepatocellular carcinoma after administration of Janus kinase (JAK) inhibitors to treat rheumatoid arthritis. A 76-year-old man was referred to our Department for pain in multiple joints and was diagnosed with rheumatoid arthritis. Blood tests revealed elevate...

Full description

Saved in:
Bibliographic Details
Main Authors: Rioko Migita, Yasutaka Kimoto, Junki Hiura, Yuta Okumura, Takahiko Horiuchi
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Case Reports in Rheumatology
Online Access:http://dx.doi.org/10.1155/2022/6852189
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850214592755531776
author Rioko Migita
Yasutaka Kimoto
Junki Hiura
Yuta Okumura
Takahiko Horiuchi
author_facet Rioko Migita
Yasutaka Kimoto
Junki Hiura
Yuta Okumura
Takahiko Horiuchi
author_sort Rioko Migita
collection DOAJ
description We report a case of rapidly progressing hepatocellular carcinoma after administration of Janus kinase (JAK) inhibitors to treat rheumatoid arthritis. A 76-year-old man was referred to our Department for pain in multiple joints and was diagnosed with rheumatoid arthritis. Blood tests revealed elevated hepatobiliary enzymes, but various tests revealed no signs suggestive of malignancy. He took baricitinib for 2 months followed by tofacitinib for 4 months. After that, he was diagnosed with hepatocellular carcinoma based on imaging findings and elevated tumor markers. This case showed the possibility of a causal relationship between JAK inhibitors and malignancy.
format Article
id doaj-art-80b20d8df551418ba13799da3ff2de41
institution OA Journals
issn 2090-6897
language English
publishDate 2022-01-01
publisher Wiley
record_format Article
series Case Reports in Rheumatology
spelling doaj-art-80b20d8df551418ba13799da3ff2de412025-08-20T02:08:50ZengWileyCase Reports in Rheumatology2090-68972022-01-01202210.1155/2022/6852189A Case of Rapidly Progressing Hepatocellular Carcinoma after Administration of JAK Inhibitors to Treat Rheumatoid ArthritisRioko Migita0Yasutaka Kimoto1Junki Hiura2Yuta Okumura3Takahiko Horiuchi4Kyushu University Beppu HospitalKyushu University Beppu HospitalKyushu University Beppu HospitalKyushu University Beppu HospitalKyushu University Beppu HospitalWe report a case of rapidly progressing hepatocellular carcinoma after administration of Janus kinase (JAK) inhibitors to treat rheumatoid arthritis. A 76-year-old man was referred to our Department for pain in multiple joints and was diagnosed with rheumatoid arthritis. Blood tests revealed elevated hepatobiliary enzymes, but various tests revealed no signs suggestive of malignancy. He took baricitinib for 2 months followed by tofacitinib for 4 months. After that, he was diagnosed with hepatocellular carcinoma based on imaging findings and elevated tumor markers. This case showed the possibility of a causal relationship between JAK inhibitors and malignancy.http://dx.doi.org/10.1155/2022/6852189
spellingShingle Rioko Migita
Yasutaka Kimoto
Junki Hiura
Yuta Okumura
Takahiko Horiuchi
A Case of Rapidly Progressing Hepatocellular Carcinoma after Administration of JAK Inhibitors to Treat Rheumatoid Arthritis
Case Reports in Rheumatology
title A Case of Rapidly Progressing Hepatocellular Carcinoma after Administration of JAK Inhibitors to Treat Rheumatoid Arthritis
title_full A Case of Rapidly Progressing Hepatocellular Carcinoma after Administration of JAK Inhibitors to Treat Rheumatoid Arthritis
title_fullStr A Case of Rapidly Progressing Hepatocellular Carcinoma after Administration of JAK Inhibitors to Treat Rheumatoid Arthritis
title_full_unstemmed A Case of Rapidly Progressing Hepatocellular Carcinoma after Administration of JAK Inhibitors to Treat Rheumatoid Arthritis
title_short A Case of Rapidly Progressing Hepatocellular Carcinoma after Administration of JAK Inhibitors to Treat Rheumatoid Arthritis
title_sort case of rapidly progressing hepatocellular carcinoma after administration of jak inhibitors to treat rheumatoid arthritis
url http://dx.doi.org/10.1155/2022/6852189
work_keys_str_mv AT riokomigita acaseofrapidlyprogressinghepatocellularcarcinomaafteradministrationofjakinhibitorstotreatrheumatoidarthritis
AT yasutakakimoto acaseofrapidlyprogressinghepatocellularcarcinomaafteradministrationofjakinhibitorstotreatrheumatoidarthritis
AT junkihiura acaseofrapidlyprogressinghepatocellularcarcinomaafteradministrationofjakinhibitorstotreatrheumatoidarthritis
AT yutaokumura acaseofrapidlyprogressinghepatocellularcarcinomaafteradministrationofjakinhibitorstotreatrheumatoidarthritis
AT takahikohoriuchi acaseofrapidlyprogressinghepatocellularcarcinomaafteradministrationofjakinhibitorstotreatrheumatoidarthritis
AT riokomigita caseofrapidlyprogressinghepatocellularcarcinomaafteradministrationofjakinhibitorstotreatrheumatoidarthritis
AT yasutakakimoto caseofrapidlyprogressinghepatocellularcarcinomaafteradministrationofjakinhibitorstotreatrheumatoidarthritis
AT junkihiura caseofrapidlyprogressinghepatocellularcarcinomaafteradministrationofjakinhibitorstotreatrheumatoidarthritis
AT yutaokumura caseofrapidlyprogressinghepatocellularcarcinomaafteradministrationofjakinhibitorstotreatrheumatoidarthritis
AT takahikohoriuchi caseofrapidlyprogressinghepatocellularcarcinomaafteradministrationofjakinhibitorstotreatrheumatoidarthritis